drugset / Trial / NCT03126019
A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to assess the objective response rate of parsaclisib treatment in participants with relapsed or refractory follicular lymphoma.
Timeline
- Start
- 2018-03-14
- Primary completion
- 2021-02-26
- Completion
- 2024-06-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Parsaclisib | Small molecule | 2.5 mg | Oral |
| Subject | Parsaclisib | Small molecule | 20 mg | Oral |